drugset / Trial / NCT00645554

A Single Dose, Cross-over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers

NCT00645554

Phase 1 Completed 2 enrolled Xian-Janssen Pharmaceutical Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this open-label, single dose, two-treatment, two-period, cross-over study is to evaluate the pharmacokinetic profile and tolerability of galantamine oral solution and galantamine tablet.

Timeline

Start
Primary completion
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Galantamine Small molecule 4 mg Oral

Indications

No indication recorded.